OUR PEOPLE: Innovation Representatives
In partnership with Entrepreneurial Postdocs of Cambridge (EPOC), the Milner Innovation Representatives are a grassroots network of early-career scientists interested in therapeutic research. They proactively reach out to other scientists in the department and facilitate interactions between academics and the Milner Institute. With the permission of the Group Leader, they communicate the desire of scientists to connect with biotech and pharma companies within the Milner Alliance.
For more information on becoming a Milner Innovation Representative, please click here.
Department of Psychiatry
Dr Chiara Guiliano
Chiara is a behavioural neuroscientist, currently employed by the University of Cambridge, Department of Psychology, as a post-doctoral Senior Research Associate and Affiliated Lecturer. She holds a degree in Pharmacy and a PhD in Pharmacology. She has research interests in the field of drug addiction. Her research to date has been focused on understanding the neural basis of compulsive drug seeking and taking, as well as binge-eating disorders and to facilitate translation of that understanding from animal models to humans by identifying new treatment targets.
Dr Jenny Hirst
Jenny is a Principal Research Associate at the Cambridge Institute for Medical Research in the laboratory of Professor Margaret Robinson. She is a cell biologist with interests in the machinery that is involved in transporting proteins between the various subcellular compartments. Her research is focused on how the loss of this machinery can lead to a number of human diseases, including hereditary spastic paraplegia, which is a rare neurodegenerative condition.
Timothy’s main research interests lie in the field of Parasitology and, particularly, of the interactions between key soil-transmitted gastrointestinal (GI) parasites of humans and animals (e.g. hookworms) and their vertebrate hosts. His research focuses on unravelling the intimate mechanisms by which these parasites ‘communicate’ with the commensal flora of the GI tract and on how these communications affect the immune status of the host.
During Aicha’s BSc and MSc in Biotechnology she focused on molecular biology and genetics in medical and pharmaceutical applications. She is now applying her molecular background in the field of translational psychiatry to study autism using cell reprogramming in her PhD. She works in the highly multidisciplinary and cross departmental environment at the Autism Research Centre and the Cambridge Stem Cell Initiative, Anne McLaren Laboratory for Regenerative Medicine at the University of Cambridge.
Dr Paulo Rodrigues
Paulo graduated in Biology in the University of the Azores (Portugal) and obtained his MSc and PhD in Biomedicine from the University of Barcelona (Spain). He is currently a Research Associate in the Vanharanta laboratory (MRC-Cancer Unit University of Cambridge). His research interests include the understanding of the transcriptional networks that develop during cancer evolution to support metastatic progression.
Dr Simon Scott
Simon has been working in the field of neurodegenerative research for over 15 years – working in academia, conducting contract work for industry, and being involved in biotech start ups. He is currently a research associate in the department of Clinical Neuroscience in Prof Roger Barker’s lab, where he conducts both lab- and clinic-based research on Parkinson’s disease (including the co-ordination of the Parkinson’s UK/BIRAX breath analysis clinical study).
Dr Sven Sewitz
Sven Sewitz is a senior postdoc at the Babraham Institute. His work combines experimental techniques (NGS, Genome Capture methods) and the bioinformatic analysis and integration of large datasets. His work focuses on fundemantal aspects of genome biology and the mechanisms of cellular development, in healthy and diseased cells.
Mo is currently a third-year PhD student in Developmental biology at the Gurdon Institute, Cambridge. Her B.Sc. is from Peking University, China. Mo is interested in finding out how her research and the work of many other scientists will benefit human health. She joined the Milner Innovation Representative programme to meet people with the same mission and help to build a bridge between the biopharma industry and academia.